GlassScriptPhysician profile
Eligio David Soliman
NPI 1134747082
$7,747.96
in general payments reported to CMS, 2019-2025
20 companies · $1,903 in 2025
The $1,903 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $80.07 · 2022: $507 · 2023: $1,666 · 2024: $3,592 · 2025: $1,903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,050 · Consulting Fee: $1,590 · Food and Beverage: $1,353 · Travel and Lodging: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,050.00 |
| Consulting Fee | $1,590.00 |
| Food and Beverage | $1,353.29 |
| Travel and Lodging | $167.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $4,746.45 | 2022-2025 | Cequr Simplicity |
| Novo Nordisk INC | $1,590.00 | 2025 | Rybelsus |
| Insulet Corporation | $207.64 | 2021-2025 | Omnipod |
| Ascensia Diabetes Care US INC. | $152.25 | 2022-2025 | |
| Medtronic, INC. | $134.94 | 2022-2024 | Minimed 780g, Inpen Smart Insulin Delivery System, Minimed 770g |
| Astrazeneca Pharmaceuticals LP | $124.89 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $94.93 | 2022-2025 | |
| Tandem Diabetes Care, INC. | $94.85 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $93.33 | 2022-2023 | Jardiance |
| Dexcom, INC. | $83.61 | 2022-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $80.80 | 2021-2023 | Afrezza |
| Xeris Pharmaceuticals, INC. | $70.40 | 2022-2024 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $57.94 | 2023 | Korlym |
| Sanofi-Aventis U.S. LLC | $39.44 | 2023 | |
| Bigfoot Biomedical INC | $35.49 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34.35 | 2022-2024 | Krystexxa |
| Amryt Pharma Holdings LTD | $34.21 | 2022 | |
| Ascendis Pharma Endocrinology INC | $27.91 | 2025 | Yorvipath |
| Abbvie INC. | $25.47 | 2023 | |
| Tolmar, INC. | $19.06 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eligio David Soliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.